HER2HER2-:

Chengxin Li1, Qianqian Yuan1, Tong Deng1

  • 1Department of Thyroid and Breast Surgery, Zhongnan Hospital Wuhan University, Wuhan, China.

PubMed
概括

与HER2-零患者相比,HER2-低乳腺癌患者的整体存活率和无病存活率有所改善. 这一发现适用于不同的激素受体状态,这表明HER2-低乳腺癌的明显预后价值.